Get the Stockscreener App
15.70
2.00%
-0.32
After Hours:
15.70
Corvus Pharmaceuticals Inc stock is traded at $15.70, with a volume of 772.62K.
It is down -2.00% in the last 24 hours and up +6.88% over the past month.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
See More
Previous Close:
$16.02
Open:
$16.24
24h Volume:
772.62K
Relative Volume:
0.58
Market Cap:
$1.32B
Revenue:
-
Net Income/Loss:
$-15.28M
P/E Ratio:
-31.02
EPS:
-0.5061
Net Cash Flow:
$-32.97M
1W Performance:
+0.51%
1M Performance:
+6.88%
6M Performance:
+108.50%
1Y Performance:
+340.39%
1-Day Range:
$15.33
$16.30
1-Week Range:
$14.11
$16.34
52-Week Range:
$3.165
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.70 | 1.35B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Goldman | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm
Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm
MSN Money - MSN
Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) to Release Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3%Here's Why - MarketBeat
CRVS stock surges 10%, hits 50-DMA for first time in a month – here’s why Goldman Sachs sees a 166% upside - MSN
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Corvus Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Chan Andrew C. - Moomoo
Corvus Pharmaceuticals (CRVS) director granted 30,000 stock options at $16.02 - Stock Titan
Corvus Pharmaceuticals (CRVS) director Andrew Chan files Form 3 - Stock Titan
BlackRock (NYSE: BLK) holds 5.39M shares of Corvus Pharmaceuticals (CRVS) - Stock Titan
Goldman Sachs initiates coverage of Corvus Pharmaceuticals (CRVS) with buy recommendation - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Corvus jumps as Goldman Sachs initiates at buy on lead asset - MSN
Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Reframing Its Immunology Strategy With Soquelitinib’s Drug‑Free Remission Narrative? - Sahm
Corvus Pharmaceuticals (NASDAQ: CRVS) outlines 2026 virtual meeting and pay vote - Stock Titan
Corvus Pharmaceuticals appoints ex-Genentech executive to board By Investing.com - Investing.com India
Corvus Pharmaceuticals Announces Board Changes and New Director - TipRanks
New Corvus (NASDAQ: CRVS) director joins as Scott Morrison exits - Stock Titan
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2%Here's Why - MarketBeat
Corvus Pharmaceuticals appoints ex-Genentech executive to board - Investing.com
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5%What's Next? - MarketBeat
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting - The Manila Times
Corvus spotlights eczema drug data, including late-breaker remission results - Stock Titan
Corvus (CRVS) Stock: Build a Position? (Smart Money Exits) 2026-04-20Social Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings - Sahm
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Corvus jumps as Goldman Sachs initiates at Buy on lead asset - Seeking Alpha
Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
Corvus (CRVS) Stock Consolidates (On the Radar) 2026-04-15Micro Trends - UBND thành phố Hải Phòng
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 4.3%Should You Sell? - MarketBeat
CRVS Technical Analysis | Trend, Signals & Chart Patterns | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
Price Action: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Aug Drivers: What are the risks of holding Corvus Pharmaceuticals Inc2026 Setups & High Accuracy Swing Trade Signals - baoquankhu1.vn
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):